Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00075057" target="_blank" >RIV/00216224:14110/14:00075057 - isvavai.cz</a>

Alternative codes found

RIV/65269705:_____/14:00061608

Result on the web

<a href="http://dx.doi.org/10.1182/blood-2013-06-511592" target="_blank" >http://dx.doi.org/10.1182/blood-2013-06-511592</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1182/blood-2013-06-511592" target="_blank" >10.1182/blood-2013-06-511592</a>

Result language

angličtina

Original language name

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

Original language description

This analysis explores the impact of early cytogenetic and molecular responses on the outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase 3 DASatinib versus Imatinib Study In treatment-Naive CML patients trial with aminimum follow-up of 3 years. Patients with newly diagnosed CML-CP were randomized to receive 100 mg dasatinib (n 5 259) or 400 mg imatinib (n 5 260) once daily. The retrospective landmark analysis included patients evaluable at the relevant timepoint (3, 6, or 12 months). Median time to complete cytogenetic response was 3 vs 6 months with dasatinib vs imatinib. At 3 and 6 months, the proportion of patients with BCR-ABL transcript levels 10% was higher in the dasatinib arm. Deeper responses at 3, 6, and 12 months were observed in a higher proportion of patients on dasatinib therapy and were associated with better 3-year progression-free survival and overall survival in both arms.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

BLOOD

ISSN

0006-4971

e-ISSN

—

Volume of the periodical

123

Issue of the periodical within the volume

4

Country of publishing house

US - UNITED STATES

Number of pages

7

Pages from-to

494-500

UT code for WoS article

000334254200013

EID of the result in the Scopus database

—